NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel
March 08, 2024 16:05 ET
|
NurExone Biologic Inc
NurExone establishing State-of-the-Art Research and Development Facility on Technion Campus in Israel
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
March 01, 2024 16:04 ET
|
NurExone Biologic Inc
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
NurExone’s Intellectual Property Portfolio Expands
February 20, 2024 16:05 ET
|
NurExone Biologic Inc
NurExone's Intellectual Property portfolio is expanding to encompass processes and compositions related to exosomes in large-scale production
NurExone Launches Licensing Efforts for ExoTherapy Platform
February 14, 2024 16:20 ET
|
NurExone Biologic Inc
NurExone Biologic launches licensing efforts for its ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
February 02, 2024 16:05 ET
|
NurExone Biologic Inc
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant for its groundbreaking ExoPTEN product
NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market
January 17, 2024 08:34 ET
|
NurExone Biologic Inc
NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
January 05, 2024 08:30 ET
|
NurExone Biologic Inc
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration
November 29, 2023 08:30 ET
|
NurExone Biologic Inc
NurExone Biologic expands its portfolio of products to address spinal cord injuries & neuron regeneration in CNS indications
NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 24, 2023 08:30 ET
|
NurExone Biologic Inc
NurExone released a corporate update and reported financial results for the quarter ended September 30, 2023.
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment
October 30, 2023 09:20 ET
|
NurExone Biologic Inc
NurExone Biologic Receive FDA Orphan-Drug Designation to its ExoPTEN Therapy for Acute Spinal Cord Injury Treatment